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OBJECTIVES: To compare the effect of monteleukast with placebo when combined with 
standard treatment of mild to moderate exacerbation of asthma by measuring modified 
pulmonary index score, PEFR and subjective improvement on a visual analog scale at 4 hours 
and 36-48 hours after intervention. 
 
METHODOLOGY: Randomised double blinded, placebo controlled study was done 
in 2015 on children aged 5-15 years  who presented with mild to moderate  
exacerbation of asthma, comparing the outcome measures when montelukast (2 doses 
, 24 hours apart) or placebo was combined with standard treatment. The primary 
outcome studied was Modified Pulmonary Index Score (MPIS) reduction from 
baseline to 4 hours. Secondary outcomes studied were comparison of PEFR and visual 
analog scale at 4 hours and 36-48 hours and MPIS at 36 hours.The need for steroid 
use in both groups were compared.  
The sample size was calculated to be 52 in each group. Data was analysed using SPSS 
software. The proportions among the two groups were compared using Chi square 
test. Independent student t test was used to measure the mean difference in the 
continuous variables. .  
 
 
RESULTS: Interim analysis of the data was done when 22 children were enrolled, 
11were in montelukast and 11 in placebo arm. The baseline characteristics between 
the two groups were similar. Interim analysis did not show statistically significant 
difference between monteleukast and placebo in the parameters assessed namely 
reduction in MPIS, peak expiratory flow rate, visual analog scale at 4 hours and after 
36 hours. However, children in monteleukast group showed a trend towards better 
outcome in all parameters assessed.  
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